16.beta.-([18F]Fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors

1993 ◽  
Vol 36 (11) ◽  
pp. 1619-1629 ◽  
Author(s):  
Henry F. VanBrocklin ◽  
Kathryn E. Carlson ◽  
John A. Katzenellenbogen ◽  
Michael J. Welch
Keyword(s):  
Estrogen Receptor ◽  
Breast Tumors ◽  
Systematic Investigation ◽  
Imaging Agents ◽  
Estrogen Receptor Positive

scholarly journals Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors

2017 ◽  
Vol 30 (8) ◽  
pp. 1078-1085 ◽  
Author(s):  
Daniel J Farrugia ◽  
Alessandra Landmann ◽  
Li Zhu ◽  
Emilia J Diego ◽  
Ronald R Johnson ◽  
...  
Keyword(s):  
Estrogen Receptor ◽  
Systemic Chemotherapy ◽  
Breast Tumors ◽  
Pathologic Response ◽  
Estrogen Receptor Positive

scholarly journals Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer

2019 ◽  
Vol 11 (1) ◽  
Author(s):  
Hilary Snider ◽  
Brithica Villavarajan ◽  
Yingwei Peng ◽  
Lois E. Shepherd ◽  
Andrew C. Robinson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Estrogen Receptor ◽  
Glucocorticoid Receptor ◽  
Promoter Methylation ◽  
Prognostic Value ◽  
Breast Tumors ◽  
Tamoxifen Treatment ◽  
Promoter Regions ◽  
Estrogen Receptor Positive

Abstract Background The glucocorticoid receptor (NR3C1, GR) is frequently downregulated in breast tumors, and evidence suggests it acts as a tumor suppressor in estrogen receptor-positive (ER+) breast cancer. We previously found that methylation of the GR promoter CpG island represses gene expression and occurs in ER+ breast tumors. In this study, the prognostic and predictive value of GR methylation was examined in ER+ patients from the CCTG MA.12 clinical trial of tamoxifen versus placebo in women with early breast cancer. Methods We developed a targeted multiplex bisulfite next-generation sequencing assay to detect methylation at multiple GR promoter regions in DNA from formalin-fixed paraffin-embedded (FFPE) samples. Following validation in a small cohort of breast tumors, ER+ FFPE tumor samples from MA.12 (n = 208) were tested. Survival analyses evaluated the impact of GR promoter methylation on patient overall survival (OS) and disease-free survival (DFS). Results An analysis of TCGA data found that GR methylation is prevalent in ER+ tumors and is associated with decreased gene expression and analysis of public microarray data (KM Plotter) linked decreased GR expression to a poor outcome. In MA.12, two GR promoter regions (U and C) each had prognostic value, but with opposite effects on the outcome. U methylation was associated with poor OS (HR = 1.79, P = 0.041) whereas C methylation was associated with better OS (HR = 0.40, P = 0.040) and DFS (HR = 0.49, P = 0.037). The classification of patients based on the methylation status of the two regions was prognostic for OS (P = 0.006) and DFS (P = 0.041) and revealed a group of patients (U methylated, C unmethylated) with very poor outcomes. Placebo-treated patients in this high-risk group had worse OS (HR = 2.86, P = 0.002) and DFS (HR = 2.09, P = 0.014) compared to the rest of the cohort. Conclusion Region-specific GR promoter methylation was an independent prognostic marker for patient survival and identified a subset of patients with poor prognosis, particularly without tamoxifen treatment. These findings provide a foundation for future studies into GR methylation as a promising prognostic biomarker in ER+ breast cancer.

Sign in / Sign up

Export Citation Format

Share Document